Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALNY Stock Forecast 2025-2026
$442.70
Current Price
$58.49B
Market Cap
Buy 21
Hold 6
Sell 1
Wall St Analyst Ratings
Distance to ALNY Price Targets
+31.0%
To High Target of $580.00
+11.8%
To Median Target of $495.00
-33.1%
To Low Target of $296.27
ALNY Price Momentum
-2.9%
1 Week Change
-3.1%
1 Month Change
+59.6%
1 Year Change
+88.1%
Year-to-Date Change
-10.7%
From 52W High of $495.55
+115.0%
From 52W Low of $205.87
📊 TOP ANALYST CALLS
Did ALNY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alnylam is one of their latest high-conviction picks.
Latest ALNY Stock Price Targets & Analyst Predictions
Based on our analysis of 47 Wall Street analysts, ALNY has a bullish consensus with a median price target of $495.00 (ranging from $296.27 to $580.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $442.70, the median forecast implies a 11.8% upside. This outlook is supported by 21 Buy, 6 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALNY Analyst Ratings
21
Buy
6
Hold
1
Sell
ALNY Price Target Range
Low
$296.27
Average
$495.00
High
$580.00
Current: $442.70
Latest ALNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2025 | Barclays | Gena Wang | Overweight | Maintains | $527.00 |
| Oct 31, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $489.00 |
| Oct 30, 2025 | Jefferies | Maury Raycroft | Buy | Maintains | $549.00 |
| Oct 17, 2025 | Truist Securities | Danielle Brill | Buy | Maintains | $535.00 |
| Oct 13, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $473.00 |
| Oct 10, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $570.00 |
| Oct 6, 2025 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $475.00 |
| Oct 6, 2025 | Stifel | Paul Matteis | Buy | Maintains | $495.00 |
| Sep 19, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $500.00 |
| Sep 17, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $520.00 |
| Sep 16, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $566.00 |
| Sep 15, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Sep 11, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $515.05 |
| Sep 8, 2025 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $470.00 |
| Sep 2, 2025 | Citigroup | David Lebovitz | Buy | Maintains | $583.00 |
| Sep 2, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $570.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $570.00 |
| Aug 6, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $475.00 |
| Aug 4, 2025 | Wolfe Research | Andy Chen | Peer Perform | Upgrade | $N/A |
| Aug 4, 2025 | Oppenheimer | Leland Gershell | Outperform | Upgrade | $490.00 |
Alnylam Pharmaceuticals Inc. (ALNY) Competitors
The following stocks are similar to Alnylam based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alnylam Pharmaceuticals Inc. (ALNY) Financial Data
Alnylam Pharmaceuticals Inc. has a market capitalization of $58.49B with a P/E ratio of 1,428.1x. The company generates $3.21B in trailing twelve-month revenue with a 1.4% profit margin.
Revenue growth is +149.3% quarter-over-quarter, while maintaining an operating margin of +29.5% and return on equity of +32.7%.
Valuation Metrics
Market Cap
$58.49B
Enterprise Value
$58.54B
P/E Ratio
1,428.1x
PEG Ratio
4.9x
Price/Sales
18.2x
Growth & Margins
Revenue Growth (YoY)
+149.3%
Gross Margin
+81.5%
Operating Margin
+29.5%
Net Margin
+1.4%
EPS Growth
+17.3%
Financial Health
Cash/Price Ratio
+4.7%
Current Ratio
2.5x
Debt/Equity
1,185.7x
ROE
+32.7%
ROA
+3.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alnylam Pharmaceuticals Inc. (ALNY) Business Model
About Alnylam Pharmaceuticals Inc.
What They Do
Develops RNA interference therapeutics for various diseases.
Business Model
Alnylam Pharmaceuticals generates revenue by developing and commercializing innovative RNAi-based therapies for a range of diseases. The company collaborates with other pharmaceutical firms and research institutions to enhance its therapeutic pipeline, aiming to address unmet medical needs and improve patient outcomes.
Additional Information
Headquartered in Cambridge, Massachusetts, Alnylam is recognized as a leader in biotechnology, focusing on genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. Its strong partnerships and collaborations, along with a robust pipeline, position the company favorably within the evolving landscape of genetic therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,230
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Country
United States
IPO Year
2004
Website
www.alnylam.comAlnylam Pharmaceuticals Inc. (ALNY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Oct 29, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Alnylam Pharmaceuticals will present at the UBS Global Healthcare Conference on November 10, 2025, and the Jefferies Global Healthcare Conference on November 19, 2025.
Why It Matters
Alnylam Pharmaceuticals' participation in major investor conferences signals potential updates on their pipeline, which could influence stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
4 days ago
Quick Summary
Alphabet's antitrust ruling allows it to retain Chrome and Android. Alnylam's shares rose after a successful Regeneron trial. AppLovin has been added to the portfolio as a major gaming ad network.
Why It Matters
The antitrust ruling reduces regulatory risk for Alphabet, potentially boosting investor confidence. Positive trial results for Alnylam enhance its market value, while AppLovin's unique position may attract investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
7 days ago
Quick Summary
Benzinga's Stock Whisper Index highlights five under-the-radar stocks weekly, utilizing proprietary data and pattern recognition for investor consideration.
Why It Matters
The Stock Whisper Index highlights undervalued stocks, providing investors with potential opportunities for growth and profit, which can influence trading strategies and market movements.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
The sector is experiencing increased stability, presenting potential profit opportunities in four identified stocks.
Why It Matters
Increased stability in a volatile sector suggests reduced risk and potential for growth, making the highlighted stocks attractive investment opportunities.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Alnylam's stock may rise after surpassing Wall Street's Q3 forecasts, driven by strong performance from its drug Amvuttra.
Why It Matters
Alnylam's strong Q3 performance and positive outlook for Amvuttra may drive stock price appreciation, indicating potential growth and investor interest.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Alnylam Pharmaceuticals held its Q3 2025 Earnings Call on October 30, 2025, featuring key executives and analysts from major financial institutions discussing company performance.
Why It Matters
Alnylam's Q3 earnings call provides insights into its financial performance and strategic direction, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ALNY Stock
What is Alnylam Pharmaceuticals Inc.'s (ALNY) stock forecast for 2026?
Based on our analysis of 47 Wall Street analysts, Alnylam Pharmaceuticals Inc. (ALNY) has a median price target of $495.00. The highest price target is $580.00 and the lowest is $296.27.
Is ALNY stock a good investment in 2026?
According to current analyst ratings, ALNY has 21 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $442.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALNY stock?
Wall Street analysts predict ALNY stock could reach $495.00 in the next 12 months. This represents a 11.8% increase from the current price of $442.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alnylam Pharmaceuticals Inc.'s business model?
Alnylam Pharmaceuticals generates revenue by developing and commercializing innovative RNAi-based therapies for a range of diseases. The company collaborates with other pharmaceutical firms and research institutions to enhance its therapeutic pipeline, aiming to address unmet medical needs and improve patient outcomes.
What is the highest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The highest price target for ALNY is $580.00 from at , which represents a 31.0% increase from the current price of $442.70.
What is the lowest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The lowest price target for ALNY is $296.27 from at , which represents a -33.1% decrease from the current price of $442.70.
What is the overall ALNY consensus from analysts for Alnylam Pharmaceuticals Inc.?
The overall analyst consensus for ALNY is bullish. Out of 47 Wall Street analysts, 21 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $495.00.
How accurate are ALNY stock price projections?
Stock price projections, including those for Alnylam Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 9:33 AM UTC